The 2026 isotretinoin trial, testing a prescription vitamin-A-based drug for severe acne, found no added benefit from 150 mg/kg over 120 mg/kg. Adults with persistent acne should not read the headline as a reason to push the total dose higher.
The trial randomized 91 adolescents and young adults with moderate to severe cystic acne to 120 mg/kg or 150 mg/kg. It tracked lesion count, severity and 12-month relapse, according to The Limbic Dermatology reporting on the Murrell trial The Limbic Dermatology report on the higher-dose comparison. Cumulative dose means total milligrams per kilogram across the whole course, and relapse was 26.7% with 120 mg/kg and 32.3% with 150 mg/kg.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the 120 versus 150 comparison measured
- How the larger cohort result fits
- Why this trial does not cover all adult acne
- What to ask about instead of a higher total
What the 120 versus 150 comparison measured
Researchers tested two total-dose goals in the same type of severe acne. All participants had moderate to severe cystic disease and were adolescents or young adults. The comparison focused on treatment response during care and relapse after care.
The Limbic Dermatology account reports lesion count and severity as response measures. It puts 12-month relapse at 26.7% for 120 mg/kg and 32.3% for 150 mg/kg. The higher total did not lower relapse in this small trial.
How the larger cohort result fits
A much larger JAMA Dermatology cohort followed 19,907 acne patients treated for at least four months, reported in the JAMA Dermatology full article. Each extra mg/kg modestly lowered relapse and retrial. The lowest relapse sat in the 120-220 mg/kg band.
The hazard ratio was 0.996 for relapse and about 0.99 for retrial per mg/kg. The NIH PMC record of the study lists 4,482 patients (22.5%) with relapse needing systemic treatment and 1,639 (8.2%) receiving a second course. A Dermatology Times summary notes higher maximum daily dose did not lower relapse or retrial among those reaching at least 120 mg/kg. The pattern points to total exposure, not daily intensity.
Why this trial does not cover all adult acne
The 91-patient trial covers adolescents and young adults with cystic disease, not all adults with persistent acne. Adult acne varies more in cause, pattern and hormones. A small cystic-acne sample cannot set rules for every adult case.
Standard care often starts at 0.5 mg/kg per day and moves toward 1 mg/kg per day based on tolerance and response, as described in the Pharmaceutical Journal best-practice guide. Treatment often continues to 120-150 mg/kg total over about 16-24 weeks. That range remains the practical anchor, not a higher target.
What to ask about instead of a higher total
Isotretinoin can severely harm an unborn baby and requires monthly monitoring under FDA iPLEDGE. Pushing past 120-150 mg/kg adds visits, lab work and burden without proven relapse benefit, a point made in the PMC review of isotretinoin safety and iPLEDGE.
Extra weeks do not buy extra protection in these data. Use your visit to focus on response, relapse plan and safety. Bring dates of past flares, prior doses and current skin products to that talk.
- Ask what total dose your course targets and why that goal fits you.
- Ask how you will track clearing and what counts as relapse.
- Review pregnancy prevention, monthly checks and side-effect limits before extending care.
You Might Also Like
- Low-Dose Isotretinoin Side Effects in the 2026 Fish Oil Trial: How Adults With Persistent Acne Can Avoid Overreading the Headline
- Fish Oil With Low-Dose Isotretinoin in a 2026 Randomized Trial: How Adults With Persistent Acne Can Avoid Overreading the Headline
- Dual-Wavelength Laser Treatment for Acne Erythema in 2026: How Adults With Persistent Acne Can Compare Treatment Options